Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholestin public comments to be accepted by FDA until Jan. 30.

This article was originally published in The Tan Sheet

Executive Summary

CHOLESTIN PUBLIC COMMENTS TO BE ACCEPTED BY FDA UNTIL JAN. 30, according to an agency notice in the Jan. 13 Federal Register. The notice invites comments on the regulatory status of the product, marketed by Pharmanex as a dietary supplement for cholesterol reduction, and provides additional time for submissions. The agency disclosed it was initiating an administrative proceeding on the issue in a Nov. 14 letter to Pharmanex and said it would target the end of 1997 for a final decision ("The Tan Sheet" Dec. 1, 1997, p. 6). The letter responded to a citizen petition from Pharmanex requesting a stay of enforcement action against Cholestin.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel